110-305-002: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Child

Grants and Contracts Details

StatusActive
Effective start/end date4/19/224/19/26

Funding

  • AbbVie Incorporated: $2.00